Video Experimental Relacionado
Updated: May 7, 2026
06:52
Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
Published on: April 28, 2023
Agentes de diagnóstico por imágenes para la enfermedad de Alzheimer: radiofármacos de cobre que se dirigen a las
James L Hickey1, SinChun Lim, David J Hayne
1School of Chemistry, ‡Bio21 Molecular Science and Biotechnology Institute, §Florey Institute of Neuroscience and Mental Health, □Department of Pharmacology, and ∥Department of Pathology, University of Melbourne, Parkville , Melbourne, Victoria, 3010, Australia.
Journal of the American Chemical Society
|September 28, 2013
Resumen
Los nuevos complejos de cobre se dirigen a las placas de amiloide-β, un sello distintivo de la enfermedad de Alzheimer. Estos nuevos ligandos muestran potencial para el diagnóstico por imágenes y estrategias terapéuticas para trastornos cerebrales.
Área de la Ciencia:
- Química Medicinal La Química Medicinal es el campo de la Química Medicinal.
- La radioquímica es la radioquímica.
- La neurociencia es la neurociencia.
Sus antecedentes:
- La enfermedad de Alzheimer se caracteriza por placas de amiloide-β en el cerebro.
- El péptido amiloide-β agregado es el componente principal de estas placas.
- Dirigirse a estas placas es crucial para el diagnóstico y la terapia de la enfermedad de Alzheimer.
Objetivo del estudio:
- Para sintetizar nuevos ligandos basados en tiosemicarbazona-piridilhidrazina.
- Para desarrollar ligandos capaces de unirse a las placas de amiloide-β.
- Para crear complejos radiometales emisores de positrones para su uso potencial en la investigación de la enfermedad de Alzheimer.
Principales métodos:
- Síntesis de nuevos ligandos de tiosemicarbazona y piridilhidrazina.
- Formación de complejos estables de cuatro coordenadas con cobre-64 ((64) Cu).
- Evaluación de la unión de la placa en el tejido cerebral humano post-mortem y la penetración de la barrera hematoencefálica en ratones.
Principales resultados:
- Sintetizó con éxito nuevos ligandos y sus complejos estables (64) Cu.
- Se demostró que dos complejos con grupos de estirilpiridina se unen a las placas de amiloide-β.
- Un complejo modificado exhibió una penetración efectiva en la barrera hematoencefálica in vivo.
Conclusiones:
- Los ligandos desarrollados y sus complejos (64) Cu son prometedores para atacar las placas amiloide-β.
- Estos hallazgos ofrecen información sobre estrategias para entregar complejos metálicos a objetivos cerebrales.
- El estudio proporciona una base para el desarrollo de nuevos agentes diagnósticos o terapéuticos para la enfermedad de Alzheimer.
Videos de Conceptos Relacionados
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...